Literature DB >> 21199457

Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration.

Kaichi Kaneko1, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Yoshie Kusunoki, Haruo Abe, Hirahito Endo, Shinichi Kawai.   

Abstract

Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. A 44-year-old male patient presented with AOSD complicated by macrophage activation syndrome after etanercept therapy. His serum tumor necrosis factor-α (TNF-α) level was increased dramatically after etanercept therapy. The clinical course of this case suggests that the increased TNF-α level by etanercept administration might cause macrophage activation syndrome in this case.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199457     DOI: 10.1111/j.1756-185X.2010.01544.x

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  8 in total

Review 1.  Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

Authors:  Ryota Sakai; Hayato Nagasawa; Eiko Nishi; Ayumi Okuyama; Hirofumi Takei; Takahiko Kurasawa; Tsuneo Kondo; Koji Nishimura; Yuichiro Shirai; Tatsuya Ito; Hideto Kameda; Tsutomu Takeuchi; Koichi Amano
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

2.  Periodontal infection in adult-onset Still's disease patient: clinical and haematological considerations.

Authors:  Larissa Pessoa; Virgilio Galvão; Clarissa Ferreira; Leopoldo Santos Neto
Journal:  BMJ Case Rep       Date:  2011-04-26

Review 3.  Treatment of adult-onset Still's disease: a review.

Authors:  Yvan Jamilloux; Mathieu Gerfaud-Valentin; Thomas Henry; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2014-12-22       Impact factor: 2.423

Review 4.  Mechanisms, biomarkers and targets for adult-onset Still's disease.

Authors:  Eugen Feist; Stéphane Mitrovic; Bruno Fautrel
Journal:  Nat Rev Rheumatol       Date:  2018-10       Impact factor: 20.543

Review 5.  Adult-onset Still's disease: A disease at the crossroad of innate immunity and autoimmunity.

Authors:  Shijia Rao; Lemuel Shui-Lun Tsang; Ming Zhao; Wei Shi; Qianjin Lu
Journal:  Front Med (Lausanne)       Date:  2022-08-22

6.  Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients.

Authors:  Mathieu Gerfaud-Valentin; Delphine Maucort-Boulch; Arnaud Hot; Jean Iwaz; Jacques Ninet; Isabelle Durieu; Christiane Broussolle; Pascal Sève
Journal:  Medicine (Baltimore)       Date:  2014-03       Impact factor: 1.889

7.  Successful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based Review.

Authors:  Eri Watanabe; Hitoshi Sugawara; Takeshi Yamashita; Akira Ishii; Aya Oda; Chihiro Terai
Journal:  Case Rep Med       Date:  2016-09-05

8.  Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Authors:  Claudia Kedor; Joachim Listing; Jan Zernicke; Anja Weiß; Frank Behrens; Norbert Blank; Joerg Christoph Henes; Joern Kekow; Andrea Rubbert-Roth; Hendrik Schulze-Koops; Eva Seipelt; Christof Specker; Eugen Feist
Journal:  Ann Rheum Dis       Date:  2020-05-13       Impact factor: 27.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.